Patents by Inventor John Spencer Emtage

John Spencer Emtage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7566771
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 28, 2009
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7262050
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: August 28, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7244615
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: July 17, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7244832
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: July 17, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7241877
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: July 10, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20040202662
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Application
    Filed: November 7, 2003
    Publication date: October 14, 2004
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 6734286
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: May 11, 2004
    Assignee: Celltech R&D Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20040076627
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-antibodies.
    Type: Application
    Filed: November 7, 2003
    Publication date: April 22, 2004
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20040071693
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24,48) and/or (49,71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46,48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis.
    Type: Application
    Filed: November 7, 2003
    Publication date: April 15, 2004
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20030199679
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF&agr;, are provided for use in diagnosis and therapy. In particular the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF&agr; antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Application
    Filed: April 22, 2003
    Publication date: October 23, 2003
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
  • Patent number: 6632927
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: October 14, 2003
    Assignee: Celltech Therapeutics Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20030039645
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF alpha , are provided for use in diagnosis and therapy. In particular the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF alpha antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Application
    Filed: February 28, 2001
    Publication date: February 27, 2003
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20020042089
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Application
    Filed: May 15, 2001
    Publication date: April 11, 2002
    Applicant: Celltech Therapeutics Limited.
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 6316227
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: November 13, 2001
    Assignee: Celltech Therapeutics Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 6180377
    Abstract: The invention describes humanized antibodies having specificity for the epitope recognised by the murine monoclonal antibody L243. Also described are processes for preparing said antibodies and pharmaceutical compositions and medical uses of said antibodies.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: January 30, 2001
    Assignee: Celltech Therapeutics Limited
    Inventors: Susan Adrienne Morgan, John Spencer Emtage, Mark William Bodmer, Diljeet Singh Athwal
  • Patent number: 6013642
    Abstract: This invention relates to the use of stroid sulphate sulphatase inhibitors which prevent the normal physiological effect of DHEA or related steroids on inflammatory responses.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: January 11, 2000
    Inventors: Roland Foulkes, John Spencer Emtage, Mark William Bodmer, Martin Rae Wales, Graham Arthur William Rook
  • Patent number: 5998586
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 7, 1999
    Assignee: Celltech Therapeutics, Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 5994510
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF.alpha., are provided for use in diagnosis and therapy. In particular, the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF.alpha. antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 30, 1999
    Assignee: Celltech Therapeutics Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
  • Patent number: 5859205
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: January 12, 1999
    Assignee: Celltech Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: RE39548
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: April 3, 2007
    Assignee: Celltech R&D Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage